PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Zacks·23h ago
More News
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Perrigo misses Q4 EPS estimates. Its 2026 sales and profit estimates are below expectations as Infant Formula headwinds persist. Shares slide on weak guidance.
Zacks·24h ago
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1d ago
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss
AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Zacks·3d ago
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
Zacks·3d ago
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
Zacks·4d ago
Assertio (NASDAQ:ASRT) Shares Up 1.7% - Still a Buy?
Assertio (NASDAQ:ASRT) Trading Up 1.7% - Still a Buy...
MarketBeat·4d ago
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.